tirzepatide cardiovascular outcomes trial 2024 Frontiers American Heart Association Scientific Sessions

SKU: 87551757126

Pay in 4 interest-free payments of $6.13 Learn more

Live Spec

American Heart Association Scientific Sessions 2024 has started off with a bang! Results are in for the SUMMIT study: Treatment with Tirzepatide (Mounjaro Zepbound) was associated with 38% in combined risk Real world efficacy of tirzepatide in patients with heart failure without diabetes ScienceDirect A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre specified exploratory analyses of the SURPASS CVOT trial The Lancet Diabetes & Endocrinology Tirzepatide Improves HFpEF Symptoms and Outcomes Cardiac Wire Tirzepatide and Cardiovascular Outcomes in Patients With Ventricular Tachycardia and Systolic Heart Failure ScienceDirect

Store: selfdriverentaluganda.com · Domain: selfdriverentaluganda.com